Carina Stanton, BSJ, MA, is a freelance science journalist based in Denver. She has been writing about science for more than 16 years, covering a range of healthcare topics, including rheumatology, surgery, nursing and executive leadership. Her work has appeared in newspapers, newsletters, trade and consumer magazines, books and peer-reviewed journals. Carina has also covered a range of other science news topics, including environmental science, marine biology and archaeology. She has conducted her own research in historical archaeology in Great Britain and Scotland and worked on dig sites in Northern Ireland and Wales. As a former mass media science and engineering fellow for the American Association for the Advancement of Science, Carina is inspired to advance the public understanding of science. When she is not working indoors, Carina is happy spending time outside with her husband and two young children to hike, mountain bike and help her children grow their passion for nature.
Results from a 20-year, cohort study add to the evidence that depression increases the risk of developing an autoimmune disease, specifically SLE in women. Lead investigator Andrea Roberts, PhD, says, “There may be direct biological effects of depression that increase the risk of autoimmune disease.”…
New research exploring the effects of etanercept on cardiovascular disease in treatment-naive, early RA patients suggests a treatment advantage with etanercept, a TNF inhibitor and methotrexate over treatment with methotrexate and a conventional synthetic disease-modifying anti-rheumatic drug…
At diagnosis, temporal artery biopsy results and large-vessel involvement of patients with giant cell arteritis may be stronger predictors of mortality than cardiovascular risk factors…
The ACR has elected a small group of division directors from across the country to serve on the Division Directors Special Committee. The goals of this committee: to better understand the needs of academic rheumatology programs and share with these programs new resources from the ACR and other organizations to support the needs of those…
New evidence from a clinical trial of rituximab has identified the pathogenetic role of B cells in the earliest, pre-arthritis stage of autoantibody-positive RA…
In a recent Phase 2 clinical trial, patient-perceived pain and function measures improved with SM04690, an injectable, disease-modifying osteoarthritis treatment currently in development…
A proof-of-concept study including 10 patients treated for dermatomyositis with tofacitinib, an FDA-approved drug for RA and psoriatic arthritis, shows strong clinical efficacy…
With more than 152,000 taken steps in four days, top honors in the first-ever ACR/ARHP Annual Meeting Walking Challenge go to Mark Phelan, MD…
With a number of new legislators and new governors sworn in this month, 2019 promises to be an exciting year for state-level rheumatology advocacy. “Now is the time to reach out and share our top issues with new legislators in your state,” suggests Joseph Cantrell, ACR senior manager of state affairs. 2019 Priorities ACR Affiliate…
Limited data are available on liver enzyme elevation in patients with RA, PsA and psoriasis being treated with tofacitinib and methotrexate. But early study findings are shedding light on the nature and risks of liver enzyme levels in these patients…